Skip to content

Management Team

Renée Aguiar-Lucander

Renée Aguiar-Lucander

Chief Executive Officer
Renée Aguiar-Lucander

Renée Aguiar-Lucander

Chief Executive Officer

Born 1962. CEO since 2017.

Education:
BA in Finance from Stockholm School of Economics. MBA from INSEAD.

Experience:
Before joining Calliditas, Renée Aguiar-Lucander was a Partner and COO of Omega Fund Management, an international venture capital company focused on investments within the life science sector. Before that, she served as a Partner in the venture capital group 3i Group plc in London, where she managed the publicly quoted assets and was co-head of the global healthcare and technology portfolio. Prior to this, Renée Aguiar-Lucander was the European Group Head and Managing Director at a global investment bank and has more than 12 years’ experience in corporate finance. Prior to her career in investment banking, she was the Head of European Sales and Marketing in a company focused on the sale of software for financial services.

Other current assignments: –

Holdings in the Company:
Renée Aguiar-Lucander holds 643,000 shares in the Company and 841,000 options.

Frank Bringstrup

Frank Bringstrup

Vice President Regulatory Affairs
Frank Bringstrup

Frank Bringstrup

Vice President Regulatory Affairs

Born 1959. VP Regulatory Affairs since 2019.

Education:
Medical education from the University of Copenhagen. He has a diploma in Managing Medical Product Innovation (MMPI) from the Copenhagen School of Economics, a diploma in business administration from Warwick University, and a post graduate specialist course in public health science from the National Board of Health, Denmark.

Experience:
Frank Bringstrup has over 17 years of experience in the pharmaceutical industry within regulatory affairs and health authority interactions. Prior to joining Calliditas, he worked in various positions at Novo Nordisk A / S. He started his professional career first as a clinic doctor and then Frederiksborg County Medical Advisor.

Holding in the Company:
Frank Bringstrup holds 8,000 shares in the Company and 135,000 options.

calliditas-management-Maria-tornsen-image

Maria Törnsén

President, North America
calliditas-management-Maria-tornsen-image

Maria Törnsén

President, North America

Born 1978. President, North America since 2024.

Education:
MSc in International Business Administration from Lund University, Sweden.

Experience:
Maria Törnsén has more than 20 years of experience in the pharmaceutical industry. Maria is currently a Board Director for Immunic Therapeutics and before joining Calliditas, she worked as Chief Commercial Officer at Passage Bio. Prior to Passage Bio, Maria held various commercial leadership roles at Sarepta, Sanofi and Shire. Maria began her career at Eli Lilly in sales and also worked at Merck KGaA in sales and marketing.

Maria Törnsén holds no shares or options in the Company.

calliditas-brian-gorman-people

Brian Gorman

Group General Counsel
calliditas-brian-gorman-people

Brian Gorman

Group General Counsel

Born 1976. Group General Counsel since 2023.

Education:
Bachelor’s Degree from Gettysburg College, J.D from Villanova University School of Law.

Experience:
Brian is an accomplished legal and business executive with more than 20 years of experience advising corporate boards and executive management teams of life science companies. He joins Calliditas after having served most recently as Executive Vice President, Corporate Development & General Counsel at Opiant Pharmaceuticals, which was acquired by Indivior PLC.  Prior to Opiant, Brian held senior legal leadership roles at Endo Pharmaceuticals, AstraZeneca and Wyeth Pharmaceuticals (now Pfizer). He began his career at the international law firm, Cleary Gottlieb Steen & Hamilton.

Holdings in the Company:
Brian Gorman holds 75,000 options.

Fredrik Johansson

Fredrik Johansson

Chief Financial Officer
Fredrik Johansson

Fredrik Johansson

Chief Financial Officer

Born 1977. CFO since 2017.

Education:
Studies in Business Law at Jönköping International Business School. Studies in Business and American law, Economics and Finance at Georgia State University, University of South Carolina and Lund University.

Experience:
Fredrik Johansson has extensive experience in executive positions, primarily within telecom and software. Previously, he was CFO and COO at Birdstep Technology/ Techstep ASA, listed on the Oslo Stock Exchange, where he, among other things, was in charge of the acquisition and reversed listing of Teki Solutions. Previous CFO positions also include Phone Family, Teligent Telecom and Wayfinder Systems.

Holdings in the Company:
Fredrik Johansson holds 42,750 shares in the Company and 305,000 options.

Richard Philipson

Richard Philipson

Chief Medical Officer
Richard Philipson

Richard Philipson

Chief Medical Officer

Born 1964. Chief Medical Officer since 2020.

Education:
BSc in Biomedical Sciences at London University and MB MS, Middlesex Hospital Medical School. Fellow of the Royal College of Physicians and Fellow of the Faculty of Pharmaceutical Medicine.

Experience:
Dr. Richard Philipson is a physician with 24 years of experience in the pharmaceutical industry from both large pharmaceutical companies and smaller biotechs. He has extensive experience in rare diseases, having brought several products from early development to the market. Prior to joining Calliditas, Richard worked as CMO with the UK-based biotech company Trizell where he led the Adstiladrin® phase 3 clinical program and Biologics License Application in non-muscle invasive bladder cancer, submitted to the FDA in September 2019. Before Trizell, he worked for Takeda as an Executive Medical Director and spent 16 years at GlaxoSmithKline, where he held a number of senior positions, including Disease Area Head and Acting Chief Medical Officer for the Rare Diseases Unit.

Before joining the industry, Richard worked as a physician in several clinical positions with various patient populations, including patients with IgA nephropathy.

Holdings in the Company: 270,000 options.

calliditas-lars-people

Lars Stubberud

Head of Techincal Operations
calliditas-lars-people

Lars Stubberud

Head of Techincal Operations

Born 1964. Head of Technical Operations since 2023.

Education:
Master of Science (candidatus pharmaciae) and PhD in Pharmaceutical Science from the University of Oslo, Norway.

Experience:
Lars Stubberud has more than 30 years experience in the pharmaceutical industry, within the broader CMC area, including Formulation Sciences, Product Development, Technology Transfer/Technical Stewardship as well as Regulatory Affairs- CMC and Quality Assurance. Prior to joining Calliditas Lars has held various positions, including leadership roles, at Nyomed AS, Norway, AstraZeneca Sweden, as well as Cubist Pharmaceuticals GmbH, Biogen International GmbH and Alexion Pharma GmbH in Switzerland.

Holdings in the company:
Lars Stubberud holds 100 000 options.

Sandra Frithiof

Sandra Frithiof

Head of Human Resources
Sandra Frithiof

Sandra Frithiof

Head of Human Resources

Born 1975. Head of HR since 2020.

Education:
Bachelor’s Degree in Human Resource Management from Örebro University, Sweden.

Experience:
Sandra Frithiof has more than 23 years of HR experience in different industries. Before joining Calliditas Sandra worked as Head of HR and COO at Ramberg Advokater. Previous HR positions also include Karolinska University Hospital, UTC, CGI and Manpower Group.

Holdings in the Company:
Sandra Frithiof holds 105,000 options.

Shareholding in the Company as of December 31, 2022.

For more information on the warrants, see section Remuneration.